Equity Profile

ONC

BeOne Medicines AG

Health CareBiotechnology$31.5B

May6Wed

Post-Earnings Recap

ReportedQ1-2026Pre-Market6:00 AM EDT

BeOne Medicines AG Beats on EPS, Stock Up 5.32%

Metric	Actual	Expected	Surprise
EPS	$3.24	$0.87	+346.90%
Revenue	—	$1.4B	—

management commentary, guidance changes, and full analysis available with Pro.

BeOne Medicines AG Beats on EPS, Stock Up 5.32%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$3.24	$0.87	+346.90%
Revenue	—	$1.4B	—

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based on numerical results only.

What It Means

BeOne Medicines AG reported a significant earnings surprise with an EPS of $3.24, far exceeding expectations. This strong performance likely contributed to the stock's 5.32% increase following the earnings release. However, the lack of revenue data and management commentary leaves some uncertainty about the company's overall performance and future direction.

Company Snapshot

BeOne Medicines AG is a biotechnology company focused on developing innovative therapies for various diseases. Operating in the health care sector, its advancements could significantly impact patient care and treatment options, particularly in areas with high unmet medical needs.

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and reflects the company's financial health.

$0.87

Revenue

Total revenue gives insight into the company's sales performance and market demand for its products.

$1.4B

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 6Q

EPS Beat Streak

EPS Beat Rate

83%

Avg EPS Surprise

+540.06%

Avg Stock Reaction

+0.16%

Last Quarter Recap

In Q4-2025, BeOne Medicines reported an EPS of $1.95, surpassing estimates by nearly 22%. However, the stock dropped 8.48% the following day, indicating market skepticism despite the strong earnings.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect BeOne Medicines to report solid earnings this quarter, with a consensus EPS of $0.87 and revenue of $1.4B. The market is closely watching for any signs of growth or challenges in their product pipeline.

Bull Case

If BeOne exceeds EPS expectations and shows strong revenue growth, it could signal robust demand for its therapies, potentially driving the stock higher.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a significant sell-off, especially given the recent volatility.

Key Metrics to Watch

EPS

$0.87

Earnings per share is a key indicator of profitability and reflects the company's financial health.

Revenue

$1.4B

Total revenue gives insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will BeOne Medicines achieve an EPS of at least $0.87 this quarter?

Meeting or exceeding this EPS target is crucial for maintaining investor confidence and could positively influence the stock price.

What insights will management provide regarding revenue growth and product pipeline?

Investors will be keen to understand the company's growth trajectory and any potential challenges, which could significantly impact future performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate BeOne's potential for growth, particularly in light of its recent strong earnings surprises.

Supporting Evidence

The company has consistently beaten EPS estimates, suggesting stronger operational performance than anticipated.

The options market is pricing in a modest move, which may not reflect the potential for a larger reaction based on historical performance.

Key Risk

If the company reports an EPS below $0.87, it could undermine the bullish sentiment and lead to a reevaluation of growth expectations.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will determine if the recent strong earnings trend can continue amidst market uncertainties.

Bull Confirmed If

Achieving an EPS of $0.87 or higher, coupled with strong revenue growth, would confirm the bullish outlook.

Bear Confirmed If

Falling short of the $0.87 EPS target or showing weak revenue could validate bearish concerns.

Pre-Earnings Positioning

Options Market

Implied Move

±4.79%

Historical Avg

±5.2%

Pricing cheap

The options market is pricing in a potential move of about 4.79% in either direction following the earnings report.

Options are pricing ±4.2% while ONC has averaged ±5.2% over the last 6 prints — setup is pricing cheap.

Detail

ATM IV

0.5%

30d HV

31.7%

Calls (500)P/C Ratio: 0.07Puts (300)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: X of Y (Z%)

This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.1%, with a raw directional average of +1.7% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BeOne beats expectations, history suggests a potential stock increase of around 3% to 5%, confirming strong demand for its products.

In-Line / Cautious

If results come in line with expectations, the stock may remain stable but could be influenced by management's commentary on future prospects.

Miss

A miss on earnings could lead to a decline of approximately 7% or more, reflecting market disappointment and concerns about the company's trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the product pipeline and upcoming launches.
2Management's outlook on market conditions and competitive landscape.
3Details on cost management and operational efficiency improvements.
4Insights into customer demand and feedback on existing therapies.
5Any changes in guidance or expectations for the remainder of the fiscal year.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

GRABReported

Grab Holdings Limited

RecapView

May4

GBDCReported

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and reflects the company's financial health.

$0.87

Revenue

Total revenue gives insight into the company's sales performance and market demand for its products.

$1.4B

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 6Q

EPS Beat Streak

EPS Beat Rate

83%

Avg EPS Surprise

+540.06%

Avg Stock Reaction

+0.16%

Last Quarter Recap

In Q4-2025, BeOne Medicines reported an EPS of $1.95, surpassing estimates by nearly 22%. However, the stock dropped 8.48% the following day, indicating market skepticism despite the strong earnings.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If BeOne exceeds EPS expectations and shows strong revenue growth, it could signal robust demand for its therapies, potentially driving the stock higher.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a significant sell-off, especially given the recent volatility.

Key Metrics to Watch

EPS

$0.87

Earnings per share is a key indicator of profitability and reflects the company's financial health.

Revenue

$1.4B

Total revenue gives insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will BeOne Medicines achieve an EPS of at least $0.87 this quarter?

Meeting or exceeding this EPS target is crucial for maintaining investor confidence and could positively influence the stock price.

What insights will management provide regarding revenue growth and product pipeline?

Investors will be keen to understand the company's growth trajectory and any potential challenges, which could significantly impact future performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate BeOne's potential for growth, particularly in light of its recent strong earnings surprises.

Supporting Evidence

The company has consistently beaten EPS estimates, suggesting stronger operational performance than anticipated.

The options market is pricing in a modest move, which may not reflect the potential for a larger reaction based on historical performance.

Key Risk

If the company reports an EPS below $0.87, it could undermine the bullish sentiment and lead to a reevaluation of growth expectations.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will determine if the recent strong earnings trend can continue amidst market uncertainties.

Bull Confirmed If

Achieving an EPS of $0.87 or higher, coupled with strong revenue growth, would confirm the bullish outlook.

Bear Confirmed If

Falling short of the $0.87 EPS target or showing weak revenue could validate bearish concerns.

Pre-Earnings Positioning

Options Market

Implied Move

±4.79%

Historical Avg

±5.2%

Pricing cheap

The options market is pricing in a potential move of about 4.79% in either direction following the earnings report.

Options are pricing ±4.2% while ONC has averaged ±5.2% over the last 6 prints — setup is pricing cheap.

Detail

ATM IV

0.5%

30d HV

31.7%

Calls (500)P/C Ratio: 0.07Puts (300)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: X of Y (Z%)

This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.1%, with a raw directional average of +1.7% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BeOne beats expectations, history suggests a potential stock increase of around 3% to 5%, confirming strong demand for its products.

In-Line / Cautious

If results come in line with expectations, the stock may remain stable but could be influenced by management's commentary on future prospects.

Miss

A miss on earnings could lead to a decline of approximately 7% or more, reflecting market disappointment and concerns about the company's trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the product pipeline and upcoming launches.
2Management's outlook on market conditions and competitive landscape.
3Details on cost management and operational efficiency improvements.
4Insights into customer demand and feedback on existing therapies.
5Any changes in guidance or expectations for the remainder of the fiscal year.